Kanoko Matsuyama

For Kanoko Matsuyama's latest contributions to The Japan Times, see below:

Pill-popping is a business worth watching for Japan's drugmakers

National Jul 12, 2017

Pill-popping is a business worth watching for Japan's drugmakers

To eke out growth in one of the developed world's most sluggish pharmaceutical markets, Japanese drugmakers are turning to the pill-popping behavior of their customers. Medication adherence is seen as an impediment to health as well as sales in Japan, and companies including Otsuka Pharmaceutical ...

Growth concerns loom for Daiichi Sankyo on drug warning

Business / Corporate Feb 9, 2015

Growth concerns loom for Daiichi Sankyo on drug warning

Daiichi Sankyo Co. risks losing a slice of revenue to generic-medicine competition next year. Now, the drugmaker's plans to fill the gap have hit a roadblock and investors worry that growth may flounder. The Tokyo-based company's best-selling medicine is set to lose patent protection in ...